Our stock is traded on the Nasdaq market under the symbol VANI.
May 22, 2003 (as legacy company Second Sight Medical Products, Inc.)
November 18, 2014 (as legacy company Second Sight Medical Products, Inc.)
December 31st
5858 Horton Street, Suite #280
Emeryville, CA 94608
United States
T: +1 818-833-5000
Brigid Makes
Chief Financial Officer
T: 818-833-5000
investors@vivani.com
Vstock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
Goodwin Procter LLP
601 Marshall Street
Redwood City, CA 94063
increases in shareholder value?
We are well-positioned for growth with a new, highly experienced leadership team and sufficient capital to support multiple milestones for our lead product, NPM-119, all while assessing strategic options for advancing Orion II.
We are pursuing candidates that seek to address indications with large market potential and unmet needs.
The Argus® II Retinal Prosthesis?
Yes, we are no longer marketing the Argus II at this time. However, we are currently exploring other options for our next-generation Orion Visual Cortical Prothesis System designed to bring artificial vision to individuals who are blind due to a broad range of causes.
The Argus® II Retinal Prosthesis?
If a patient is currently using The Argus® II Retinal Prosthesis and one or more components malfunction, please contact us because we may be able to provide replacement parts and other forms of support.
continuing to be actively developed?
We are currently identifying and executing strategic options for advancing Orion II, an improved follow-on candidate that leverages the encouraging, early feasibility data already generated from Orion.